nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "Eating Disorders"

 

Studies Show Psilocybin Therapy Has Potential For Anorexia Nervosa And Severe Treatment-Resistant Depression
May 18, 2022   

Recent positive data was announced from two investigator-initiated studies demonstrating the potential of COMP360, a psilocybin therapy for anorexia nervosa and severe treatment-resistant depression. These two studies provided support for continued research at a larger scale to elucidate the therapeutic potential of psilocybin...
 Continue reading
MDMA-Assisted Therapy Significantly Reduces Eating Disorder
April 10, 2022   

IThe comorbidity of Post-Traumatic Stress Disorder (PTSD) and Eating Disorders (EDs) has been well studied. This relationship is hypothesized to exist due to an overlap in distinct risk factors including female gender, familial history of psychiatric disorders, lack of social support, and a history of trauma...
 Continue reading (Members only)
National Eating Disorders Awareness Week
February 21, 2022   

Less than half of individuals with an eating disorder seek treatment. As clinicians we need to help raise awareness, fight stigma, and empower ourselves to provide these patients the support they need...
 Continue reading
The Impact of Alcohol and Other Substance Use Disorders on Mortality in Patients With Eating Disorders
January 27, 2022   

Eating disorders are highly associated with mortality, and anorexia nervosa is the second most lethal psychiatric disorder, surpassed only by substance use disorder (SUD). Patients with eating disorders frequently have comorbid SUDs. In a recent retrospective cohort study using...
 Continue reading
Time Course of Relapse Following Acute Treatment for Anorexia Nervosa
August 13, 2021   

Anorexia nervosa is a devastating eating disorder and determining a path to recovery is essential. In this study, the researchers sought to find the “point of rarity” -a point in remission in which the patient is unlikely to relapse in order to help determine at what point in remission a patient could be considered to be recovered. The study included...
 Continue reading
Medical Admissions Among Adolescents With Eating Disorders During the COVID-19 Pandemic
July 27, 2021   

The COVID-19 pandemic has reportedly been associated with worsening symptoms of eating disorders in both adults and adolescents. In a recent study, a chart review of patients ages 10-23 admitted to a children’s hospital for restrictive eating disorders from March 2017 to March 2021 was conducted. Eating disorder-related medical admissions at the hospital increased significantly during the...
 Continue reading (Members only)
Genetic And Phenotypic Assessments May Inform Early Diagnoses Of Eating Disorder
January 18, 2021   

Eating disorders are common and disabling psychiatric disorders that emerge in late adolescence. The current study identified risk factors and correlates of subclinical disordered eating behaviors (DEBs) in adolescents for the purpose of informing early detection and targeted interventions. A multicenter prospective...
 Continue reading (Members only)
FDA Warns of Possible Increased Risk of Cancer With Lorcaserin
January 30, 2020   

In 2016, the World Health Organization reported that more than 1.9 billion adults were overweight and of these over 650 million were classified as obese. Overweight and obese patients are at increased risk of developing a host of cardiometabolic diseases and certain cancers, which subsequently increases...
 Continue reading
Highlights from the 2017 APA Annual Meeting
June 8, 2017   

The 2017 APA annual meeting, held in NEI's hometown of San Diego, was themed "Prevention Through Partnership" and included more than 400 sessions. Here, we provide highlights of the meeting, including NEI's podcast interviews with expert presenters, key research from the poster sessions, and NEI's debut live concert--the NEI PsychopharmaJam.
 Continue reading
September News and New Research
September 1, 2014   

SSRI discontinuation before pregnancy does not reduce risk of miscarriage, US FDA approves Contrave for weight management, maternal immune activation and increased risk for schizophrenia in offspring, and other news.
 Continue reading (Members only)
Top of Page